Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Pneumococcal polysaccharide vaccine Stories

2009-05-05 08:39:40

Infants who receive the pneumococcal conjugate vaccine (PCV) following the combination vaccine for diphtheria, polio, tetanus, pertussis and Haemophilus influenzae type b (DPTaP-Hib vaccine) appear to experience less pain than those who are immunized in the opposite order, according to a report in the May issue of Archives of Pediatrics & Adolescent Medicine, a theme issue on vaccines. Injections are the most painful common medical procedure conducted in childhood, according to background...

2009-03-31 08:30:00

- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease - COLLEGEVILLE, Pa., March 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Prevnar 13(TM), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein). Last year, the FDA granted Prevnar 13 Fast Track...

2009-01-16 21:26:43

Researchers say a pediatric vaccine has been effective in reducing the rate of pneumococcal meningitis in the United States. The study, published in the New England Journal of Medicine, said the vaccine prevents several common types of meningitis and has helped reduce the rate of another strain of meningitis that affects children and adults. The University of Pittsburgh School of Medicine said a review of 1,379 cases of pneumococcal meningitis from 1998 through 2005 shows rates of the disease...

2009-01-05 23:36:47

Commonly used pneumococcal polysaccharide vaccines do not appear to be effective in preventing pneumonia, Swiss and British researchers said. Dr. Matthias Egger of the University of Bern, Switzerland, and colleagues said that in many industrialized countries, pneumococcal vaccines are currently recommended to help prevent pneumonia in those age 65 and older, and for younger people with increased risk due to conditions like HIV. The study, a systematic review and meta-analysis, looked at 22...

2008-10-27 12:00:29

WASHINGTON, Oct. 27 /PRNewswire-FirstCall/ -- Data from a pivotal trial and three other Phase 3 studies presented today indicate that Wyeth's investigational 13-valent pneumococcal conjugate vaccine (PCV13) may offer broader protection against pneumococcal disease (PD) in infants and young children compared to Prevnar(R), Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein). Specifically, the data indicate that PCV13 may be as effective as Prevnar (also referred to as PCV7)...

2008-10-23 09:00:10

The U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously yesterday to recommend that adults ages 19 to 64 with asthma receive pneumococcal polysaccharide vaccine (PPSV23), known as PNEUMOVAX(R) 23 (Pneumococcal Vaccine Polyvalent). Merck & Co., Inc. is the sole supplier of PNEUMOVAX 23 in the United States. The ACIP based this recommendation on study data that showed an increased risk of pneumococcal disease among...

7cc8dff5c1bea6a0c998d234e5f1f33f1
2008-10-23 08:20:00

A vaccination to protect against the bacteria that can cause pneumonia, meningitis and other diseases is now available for smokers. A government panel recommends that adult smokers under the age of 65 be given the pneumococcal vaccine which is already administered to anyone 65 or older.  These pneumococcal infections affect the elderly in particular and are common complications of the flu and are top killers among the diseases that can be prevented by vaccination.  Smokers are...

2008-09-24 12:00:37

U.S. scientists say the discovery of a new mechanism of immunity suggests a more effective pneumococcal vaccine might be in the offing. Children's Hospital Boston and Harvard School of Public Health researchers say there might be a better way to protect people against Streptococcus pneumoniae infection. They said the current vaccine, Prevnar, is expensive and covers only 7 of the 91 known pneumococcal strains. Dr. Richard Malley and medical researcher Marc Lipsitch discovered that, in...

2008-09-23 09:00:15

COLLEGEVILLE, Pa., Sept. 23 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia -- the leading cause of bacterial pneumonia in adults. In Europe and the United States, pneumococcal pneumonia is the most common community-acquired bacterial pneumonia, for which the...

2008-09-15 12:00:35

COLLEGEVILLE, Pa., Sept. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced that South Africa has initiated an immunization program against pneumococcal disease with PREVENAR(R) (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed), a vaccine which helps protect infants and young children against the seven vaccine serotypes causing the majority of pneumococcal disease worldwide. The South African government launched the pneumococcal disease...